



ARSEUS
Driving superior care

Press Release

Regulated information

DISCLOSURE OF RECEIVED NOTIFICATION

Waregem (Belgium) / Rotterdam (Netherlands)¹, 16 April 2014 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received notifications (above 3%) on 11 April 2014 from AXA S.A. and on 16 April 2014 of Carmignac Gestion concerning the acquisition of voting securities.

We are delighted to announce that on 11 April AXA S.A. reported a shareholding of 4.51% and on 16 April Carmignac Gestion reported a shareholding of 4.45% in Arseus NV. On 9 April the shareholding of JP Morgan Asset Management UK Ltd. has fallen below the disclosure threshold of 3%.

Based on the denominator of 31,358,358 (total number of voting rights) and the relevant notifications that Arseus received, the shareholder structure as of 16 April 2014 is as follows:

	Number of shares	% of effective voting rights
BNP Paribas Investment Partners SA	1,609,182	5.13%
AXA S.A.	1,413,820	4.51%
Carmignac Gestion	1,396,407	4.45%
Fidelity Management and Research (FMR LLC)	1,223,000	3.90%
Arseus NV (treasury shares)	881,378	2.81%
Public	24,834,571	79.20%
Total	31,358,358	100.00%

The original notification forms are available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

¹ This press release was sent out by Arseus NV and Arseus BV.

For more information:

Marieke Palstra

Director Investor Relations

+31 88 33 11 213 (Office)

marieke.palstra@arseus.com

Arseus profile

Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.